Lexeo Therapeutics reported cash from operations of -$17.60M and free cash flow of -$17.60M for the quarter ended Jun 2026, up 35.4% year over year. This cash flow statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Net Income | -17.05M | -14.58M | -18.66M | -13.44M | -20.11M | -14.19M | -21.68M | -21.24M | -29.49M | -25.92M | -32.66M | -26.10M | -20.28M | -20.92M | -20.20M | -25.87M |
| Share-based Compensation | 0.43M | 0.52M | 0.40M | 0.97M | 2.32M | 0.80M | 3.31M | 3.46M | 3.79M | 3.51M | 3.70M | 3.07M | 4.48M | 2.71M | 6.36M | 6.47M |
| Cash from Operations | -16.63M | -18.37M | -13.19M | -13.95M | -13.98M | -14.87M | -20.15M | -17.81M | -28.33M | -21.72M | -27.22M | -29.55M | -20.08M | -21.14M | -17.60M | |
| Depreciation, Depletion & Amortization | ||||||||||||||||
| Amortizatization of Intangibles | 0.05M | 0.30M | 0.32M | 0.08M | 0.08M | 0.33M | 0.32M | 0.08M | 0.08M | 0.37M | 0.36M | 0.08M | 0.08M | 0.39M | 0.39M | 0.08M |
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.06M | 0.06M | 0.06M | 0.08M | 0.08M | 0.07M | 0.08M | 0.08M | 0.07M | 0.06M | 0.06M | 0.07M | 0.07M | 0.07M | 0.07M | |
| Change in Working Capital | ||||||||||||||||
| Change in Account Payables | -1.22M | 1.04M | -1.91M | 0.29M | 0.39M | 0.64M | 1.06M | 2.72M | -2.04M | 5.14M | 8.36M | -15.27M | 0.20M | -1.60M | 0.83M | |
| Change in Accured Expenses | -0.91M | -1.79M | 1.20M | 4.80M | -2.12M | 3.88M | -3.87M | 5.27M | -1.92M | 2.31M | -7.14M | 1.00M | -0.62M | -1.09M | 0.69M | |
| Change in Taxes | 0.14M | 0.14M | ||||||||||||||
| Other Working Capital Changes | 0.83M | -0.52M | -0.09M | -0.48M | -0.32M | -0.32M | -0.34M | -0.31M | 2.66M | 0.36M | 2.20M | -3.67M | 3.11M | 1.12M | -1.93M | |
| Investing Activities | ||||||||||||||||
| Capital Expenditures | 0.03M | 0.01M | 0.04M | 0.02M | 0.04M | 0.18M | 0.21M | 0.08M | 0.29M | 0.04M | 0.01M | |||||
| Change in Acquisitions & Divestments | 15.60M | 16.30M | 35.30M | 38.33M | 27.50M | 26.24M | ||||||||||
| Cash from Investing Activities | -0.11M | -0.05M | -0.07M | -0.19M | -0.22M | -0.08M | -93.58M | 15.60M | -39.17M | 35.01M | -101.69M | 27.46M | 14.26M | |||
| Financing Activities | ||||||||||||||||
| Other financing activities | 0.03M | 0.01M | 0.01M | 0.03M | 100.20M | 88.75M | 6.25M | 0.03M | 79.97M | 2.45M | ||||||
| Change in Capital Stock | ||||||||||||||||
| Net Shares Issued and Repurchased | 0.34M | 1.23M | 0.99M | 1.52M | 0.99M | 1.45M | 2.23M | |||||||||
| Net Equity Issued and Repurchased | 0.17M | -0.17M | 0.27M | -0.00M | 0.14M | 25.00M | ||||||||||
| Misc. | ||||||||||||||||
| Cash from Financing Activities | -0.08M | -0.10M | -0.09M | 3.91M | 100.07M | 88.65M | 0.29M | -0.07M | -0.10M | 0.01M | 72.96M | 0.05M | 143.77M | 2.45M | 24.40M | |
| Change in Cash | -16.81M | -18.47M | -13.32M | -10.09M | 86.02M | 73.59M | -20.08M | -17.96M | -122.01M | -6.11M | 6.57M | 5.52M | 22.00M | 8.77M | 21.07M | |
| Free Cash Flow | -16.65M | -18.39M | -13.23M | -13.97M | -14.02M | -15.05M | -20.36M | -17.89M | -28.33M | -21.72M | -27.22M | -29.84M | -20.08M | -21.18M | -17.60M | |
| Net Cash Flow | -16.81M | -18.47M | -13.29M | -10.09M | 86.02M | 73.59M | -20.08M | -17.96M | -122.01M | -6.11M | 6.57M | 5.52M | 22.00M | 8.77M | 21.07M |